FDA Grants Priority Review for First Targeted Therapy for Severe Genetic Epilepsies

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

A new drug is being fast-tracked for children with two severe, life-threatening genetic forms of epilepsy that currently have no targeted treatments.

Priority FDA Review.The FDA is expediting its decision to September 2026. This speeds up the process to get a potential treatment to families who currently have no approved therapies targeting these specific conditions.
First Targeted Therapy.Relutrigine is the first drug designed specifically for SCN2A and SCN8A epilepsies. Before this, doctors could only use generic anti-seizure medications that are often ineffective for these genetic causes.
Strong Trial Results.The EMBOLD study was stopped early because relutrigine worked so well. This means the evidence of benefit was clear enough to halt the trial and move directly to seeking approval, a significant milestone.
Addresses Fatal Conditions.These developmental epilepsies are severe and can be fatal in childhood. A drug showing robust efficacy offers real hope for reducing seizures and potentially improving survival and quality of life.

The US Food and Drug Administration has accepted a new drug application for priority review of relutrigine, a potential first-of-its-kind treatment for two severe and often fatal genetic epilepsies of childhood. The FDA has set a target decision date of September 27, 2026, for the therapy aimed at SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), which currently have no approved targeted treatments.

The application is supported by data from the EMBOLD study, which was stopped early due to clear evidence of efficacy. In this trial, relutrigine demonstrated robust short- and long-term improvement in motor seizures for a heavily pre-treated patient population. Some patients with SCN2A- and SCN8A-DEE even maintained seizure freedom. The drug has received multiple regulatory designations, including Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease status, underscoring the urgent need for new therapies.

Relutrigine works as a precision sodium channel modulator, specifically designed to inhibit the persistent sodium current believed to be a key driver of seizures in these severe DEEs. Its mechanism aims to selectively calm hyperexcitable neurons associated with the genetic mutations without broadly affecting normal brain activity. In preclinical models, it showed dose-dependent inhibition of seizures up to complete control.

If approved, relutrigine would become the first disease-modifying therapy specifically for SCN2A and SCN8A DEEs, offering hope for families who currently rely on broad-spectrum antiseizure medications with limited efficacy. The approval would also make the therapy eligible for a Pediatric Review Voucher. Beyond these specific conditions, relutrigine is being investigated in a broader range of DEEs through the ongoing EMERALD trial, with results expected by the end of 2026.

The FDA's priority review accelerates the timeline for a decision on this application. While the review process continues, the development marks a significant advance in precision neuroscience for some of the most challenging childhood epilepsies, moving closer to a tailored therapeutic option where none currently exists.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.